Clinical Trials

Family Study of Lymphoproliferative Disorders

Location:

Trial status:

Open for Enrollment

Why is this study being done?

Blood and lymph node cancers can begin in either the lymphatic tissues (as in the case of lymphoma) or in the bone marrow (as with leukemia and myeloma), and they all are involved with the uncontrolled growth of white blood cells. There are many subtypes of these cancers, e.g., chronic lymphocytic leukemia and non-Hodgkin lymphoma. Since there is evidence that these cancers cluster in families, this study aims to understand how genetics and environmental exposures contribute to the development of these cancers.

Who is eligible to participate?

At least 2 living, blood related relatives, affected with a lymphoproliferative disorder.

What is involved?

If a patient agrees to participate in this study, we would ask the following:

• Answer questions about their health and family history of cancer. Answering these questions may take about 45-60 minutes of time to complete. A questionnaire that contains the questions will be mailed to patient. The patient may answer the questions by filling out this questionnaire and returning it in the enclosed envelope, or they may answer the questions, at their convenience, on the telephone.


• Donate a sample of the patient's blood and cheek cells. A small amount of blood, not greater than 50 ml (about 2 ounces or 4 tablespoons), will be drawn from the patient's vein in the forearm. Cheek cells will be obtained by having the patient swish about one tablespoon of mouthwash inside of their mouth and then discharging it into a collection container. Part of the blood or cheek cells obtained from the patient may be used in studies to determine if there is a genetic contribution to the increased risk of the types of cancers or related conditions present in members of their family. In addition, if the patient has had medical care for blood or lymph node cancer or related illnesses, we may also ask for their written consent to obtain medical records and pathology material related to that care.

How long is the study?

Patients will be in this study until blood and cheek cell samples have been collected and the questionnaire information has been obtained, a patient request to withdraw from the study, or it is felt by the investigator to be in the patient's best interest to discontinue, or the study has ended.

Last updated: 12/28/2012

NCT ID: NCT00626496

IRB Number:489-04